Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study
-
Published:2023-06-19
Issue:10
Volume:42
Page:2905-2914
-
ISSN:0770-3198
-
Container-title:Clinical Rheumatology
-
language:en
-
Short-container-title:Clin Rheumatol
Author:
Tesch FalkoORCID, Ehm FranzORCID, Vivirito Annika, Wende DannyORCID, Batram ManuelORCID, Loser Friedrich, Menzer Simone, Jacob JosephineORCID, Roessler MartinORCID, Seifert Martin, Kind Barbara, König Christina, Schulte Claudia, Buschmann Tilo, Hertle Dagmar, Ballesteros Pedro, Baßler Stefan, Bertele Barbara, Bitterer Thomas, Riederer Cordula, Sobik Franziska, Reitzle LukasORCID, Scheidt-Nave ChristaORCID, Schmitt JochenORCID
Abstract
Abstract
Objectives
To investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without COVID-19, a large cohort study was conducted.
Method
A cohort was selected from German routine health care data. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19.
Results
In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69–15.42) and matched control groups (IR=10.55, 95% CI: 10.25–10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune diseases of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune disease.
Conclusions
SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection.
Key Points• In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37–48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group.• COVID-19 showed the strongest association with vascular autoimmune diseases.
Funder
Bundesministerium für Gesundheit Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference36 articles.
1. Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23:3–20. https://doi.org/10.1038/s41580-021-00418-x 2. World Health Organization (2021) A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization 3. Global Burden of Disease Long COVID Collaborators (2022) Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328:1604–1615. https://doi.org/10.1001/jama.2022.18931 4. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong AS, Silverwood RJ, Di Gessa G, Bowyer RC (2022) Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun 13:3528. https://doi.org/10.1038/s41467-022-30836-0 5. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J, Cao B (2022) Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 10:863–876. https://doi.org/10.1016/s2213-2600(22)00126-6
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|